[Federal Register Volume 69, Number 243 (Monday, December 20, 2004)]
[Notices]
[Page 75996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-27781]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: 4' and 4',4''-
substituted-3-[alpha]-(diphenylmethoxy) Tropane Analogs as Cocaine 
Therapeutics

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in of 
U.S. Patent 5,792,775, issued on August 11, 1998, entitled, ``4' and 
4',4''-substituted-3-[alpha]-(diphenylmethoxy) tropane analogs as 
cocaine therapeutics' to Phase2 Discovery, having a place of business 
in the state of Ohio. The field of use may be limited to the treatment 
of Attention Deficit Hyperactivity Disorder (ADHD). The United States 
of America is the assignee of the patent rights in this invention. This 
announcement is the first notice to grant an exclusive license to this 
technology.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before February 
18, 2005, will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Pradeep Ghosh, J.D., Ph.D., M.B.A., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5282; Facsimile: (301) 402-0220; e-
mail: <a href="/cdn-cgi/l/email-protection#c7a0afa8b4afb7b587aaa6aeabe9a9aeafe9a0a8b1"><span class="__cf_email__" data-cfemail="dfb8b7b0acb7afad9fb2beb6b3f1b1b6b7f1b8b0a9">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: This technology relates to a family of 
tropane analogs that bind to dopamine transporters and can be used to 
image dopamine transporter binding sites, and to diagnose and/or 
monitor neurodegenerative disorders and developmental disabilities like 
ADHD. ADHD is a neurobiological-based developmental disability 
characterized by inattentiveness, impulsivity, and hyperactivity.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 13, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-27781 Filed 12-17-04; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>